This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Should You Retain MEDNAX (MD) Stock in Your Portfolio?
by Zacks Equity Research
Riding high on its rising revenue stream and inorganic growth profile, MEDNAX (MD) holds potential to benefit its investors.
HCA Healthcare Acquires Valify to Rein in Medical Costs
by Zacks Equity Research
HCA Healthcare (HCA) completes the buyout of technology company Valify to identify opportunities for reducing expenses.
Why Should You Hold HCA Healthcare in Your Portfolio Now?
by Zacks Equity Research
Riding high on its growing revenues and a firm capital position, HCA Healthcare (HCA) holds potential to reap benefits for investors.
MEDNAX Expands Further in Florida With Radiology Affiliation
by Zacks Equity Research
MEDNAX (MD) forms an association with Boca Radiology Group to strengthen its radiology business in Florida.
MEDNAX (MD) Catches Eye: Stock Jumps 8.1%
by Zacks Equity Research
MEDNAX (MD) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Here's Why Should You Hold MEDNAX (MD) in Your Portfolio
by Zacks Equity Research
Riding high on its solid top line as well as strategic buyouts, MEDNAX (MD) holds enough potential to generate returns for investors.
Why Is Mednax (MD) Up 18.9% Since Last Earnings Report?
by Zacks Equity Research
Mednax (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MEDNAX (MD) Ties Up With Homestead to Expand in Florida
by Zacks Equity Research
MEDNAX (MD) collaborates with Associated Pediatricians of Homestead to provide clinical services and expand presence in Florida.
MEDNAX's Ratings Get Affirmed by Moody's, Outlook Negative
by Zacks Equity Research
MEDNAX (MD) receives rating affirmations from Moody's. However, the outlook is changed to negative.
MEDNAX (MD) Q3 Earnings In Line With Estimates, Decline Y/Y
by Zacks Equity Research
MEDNAX's (MD) results reflect escalating expenses in the third quarter.
Mednax (MD) Q3 Earnings Meet Estimates
by Zacks Equity Research
Mednax (MD) delivered earnings and revenue surprises of 0.00% and 1.75%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for MEDNAX (MD)
by Zacks Equity Research
MEDNAX (MD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Cigna (CI) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Cigna (CI) Q3 earnings are likely to have benefited from higher contribution across all its segments and effect of share buyback.
What's in Store for Molina Healthcare (MOH) Q3 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) third-quarter results are likely to be affected by soft revenues, partly offset by improved marketplace business.
What to Expect for WellCare Health's (WCG) Earnings in Q3
by Zacks Equity Research
WellCare Health's (WCG) Q3 results are likely to reflect increased revenues and higher membership, partly offset by elevated expenses.
Teladoc (TDOC) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Teladoc (TDOC) Q3 earning are likely to have benefited from increased membership and visits, and accretive effect of earlier acquisitions.
Mednax (MD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Mednax (MD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HCA Healthcare (HCA) to Post Q3 Earnings: What to Expect
by Zacks Equity Research
HCA Healthcare's (HCA) third-quarter results are likely to reflect elevated expenses, partly offset by higher topline from increase in admissions and licensed beds.
Anthem's (ANTM) Q3 Earnings Beat Estimates, Improve Y/Y
by Zacks Equity Research
Anthem's (ANTM) third-quarter earnings gain from increased revenues.
Centene's (CNC) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Centene's (CNC) third-quarter earnings gain traction from higher revenues.
What to Expect for Universal Health's (UHS) Q3 Earnings
by Zacks Equity Research
Universal Health (UHS) is likely to have benefited from strong segmental performances at Acute Care and Behavioral Health in Q3, partly offset by high costs.
Anthem (ANTM) Gears Up for Q3 Earnings: What's in Store?
by Zacks Equity Research
Anthem (ANTM) is likely to have gained from solid revenues in the third quarter.
What's in the Cards for Centene's (CNC) Earnings in Q3?
by Zacks Equity Research
Centene's (CNC) third-quarter earnings are likely to have grown on the back of solid revenues.
MEDNAX (MD) to Sell MedData for Focusing on Core Business
by Zacks Equity Research
MEDNAX (MD) to divest its billing services business for streamlining its operations.
MEDNAX Teams Up With CENTA to Expand Services in Florida
by Zacks Equity Research
MEDNAX (MD) inks a partnership deal with CENTA to strengthen its profile of varied healthcare solutions in Florida.